Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
6(75%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
7
88%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

0

Mid Stage

7

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 3Large-scale testing
7(87.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Completed(1)

Detailed Status

Recruiting5
Not yet recruiting1
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 37 (87.5%)

Trials by Status

not_yet_recruiting113%
recruiting563%
completed113%
active_not_recruiting113%

Recent Activity

6 active trials
Showing 5 of 8
recruitingphase_3

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323
recruitingphase_3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214
not_yet_recruitingphase_3

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

NCT07456033
recruitingphase_3

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT07177339
recruitingphase_3

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06979323Phase 3

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Recruiting
NCT06961214Phase 3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Recruiting
NCT07456033Phase 3

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

Not Yet Recruiting
NCT07177339Phase 3

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Recruiting
NCT05334368Phase 3

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Recruiting
NCT05263934Phase 3

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Active Not Recruiting
NCT06959095Phase 3

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

Recruiting
NCT05602025Phase 1

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8